Verdopplung
Seite 33 von 86 Neuester Beitrag: 24.04.21 23:04 | ||||
Eröffnet am: | 16.07.16 11:13 | von: nemo140262 | Anzahl Beiträge: | 3.136 |
Neuester Beitrag: | 24.04.21 23:04 | von: Jessicavfom. | Leser gesamt: | 525.522 |
Forum: | Hot-Stocks | Leser heute: | 167 | |
Bewertet mit: | ||||
Seite: < 1 | ... | 30 | 31 | 32 | | 34 | 35 | 36 | ... 86 > |
http://www.fool.com/investing/2016/11/01/...nc-tumbled-12-on-mon.aspx
At this point, nothing has materially changed for Valeant or its business model, since Wall Street is merely digesting rumors of what could happen. However, if charges were to be filed against Valeant's former execs, there is a possibility that the company itself could wind up facing repercussions that could include fines and/or sales restrictions. Neither would be preferable, given the company's relatively small cash position relative to its $30.77 billion in debt as of the end of the second quarter.
Ich hoffe, dass die am 8. ein Feuerwerk an guten Nachrichten rauslassen, inkl. asset sales.
das wäre dann die Überraschung auf die ich insgeheim glaube...
kaufe auch grade nach...
diplom - geh doch mal mehr ins Detail(Enron-Valeant) anstatt dich nur immer in 1 Satz Aussagen zu ergötzen.
wäre gespannt was da dann kommt von dir.
Jetzt muss nur noch die Richtung stimmen, Potenzial ist meiner Meinung nach vorhanden :-)
3 x den Firmennamen hier in die Runde geworfen, is ziemlich dünne!
Salix strauchelt sowieso massiv. Wäre also kein Verlust.
zu #815: "wäre also kein Verlust"
Naja, also wenn es wirklich "bloß" 10 Mrd. geben würde. Inkl. Schulden hat Valeant voriges Jahr 14 Mrd. für Salix bezahlt... ;-)
http://www.handelsblatt.com/unternehmen/industrie/...ix/11408892.html
Valeant jumps on news on potential Salix sale for $10B
http://seekingalpha.com/news/...tial-salix-sale-10b-shares-16-percent
wsj ist bei vrx ja immer ziemlich nah dran...
"...in advanced talks..."
"...$8.5 billion in cash and future royalty payments to Valeant, the people said. There is no guarantee the companies will reach a deal and, indeed, there is another unnamed potential bidder in the mix, according to a person familiar with the matter...."
"...It would also likely allow Valeant’s new chief executive, Joseph Papa, to focus on rebuilding Valeant’s core franchises in skin and eye drugs, which include Bausch & Lomb brands, have been struggling...."
"...For Takeda, the purchase would come after it lost out on earlier attempts to buy Salix and deliver big-selling gastrointestinal drugs it has been seeking to bolster its lineup of stomach remedies...."
wie gesagt, 10 mrd wären vollkommen i.O.